Funding for this research was provided by:
Noctrix, Inc.
Article History
Received: 23 August 2023
Accepted: 20 September 2023
First Online: 12 October 2023
Declarations
:
: Wing Tech Inc. (Anne M. Ryschon, Khoa N. Cao, Jan B. Pietzsch) provided health-economic consulting services to Noctrix, Inc. AR is an investigator in the underlying RESTFUL study.
: The underlying RESTFUL clinical study from which data for this analysis were obtained was conducted in accordance with the International Conference on Harmonization guidelines on good clinical practice and the Declaration of Helsinki. The study protocol and informed consent were approved by a central institutional review board (Advarra, Columbia, MD, USA). All participants provided informed consent.